Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 131 Brain Neoplasms 128 Prostatic Neoplasms 108 Neoplasm Metastasis 88 Lung Neoplasms 73 Carcinoma, Hepatocellular 71 Pancreatic Neoplasms 69 Breast Neoplasms 49 Melanoma 44 Carcinoma, Renal Cell 36 Neoplasms 34 Colorectal Neoplasms 26 Squamous Cell Carcinoma of Head and Neck 25 Glioblastoma 24 Liver Neoplasms 20 Head and Neck Neoplasms 17 Small Cell Lung Carcinoma 15 Sarcoma 13 Kidney Neoplasms 13 Glioma 12 Urinary Bladder Neoplasms 10 Recurrence 9 Gliosarcoma 8 Ovarian Neoplasms 7 Central Nervous System Neoplasms 7 Adenocarcinoma of Lung 7 Adenocarcinoma 7 Radiation Injuries 6 Prostate Cancer Metastatic 6 Neuroma, Acoustic 6

Interventions

Sorafenib 2 nimotuzumab 1 lenvatinib 1 atezolizumab 1 Tirapazamine 1 Stents 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × Radiosurgery × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡